Europe and the United States account for more than 80% of global sales of new medicines, 75% of global R&D in life sciences, and create and sustain over 1.5 million direct jobs.1 The Transatlantic Trade and Investment Partnership (TTIP) could significantly boost the world’s largest trading relationship, spur transatlantic investment in life sciences, and foster research cooperation, resulting in improved healthcare and enhanced patient access to innovative medicines on both sides of the Atlantic. TTIP also has the potential to set global standards in key areas.

Despite the potential benefits of this opportunity, questions have been raised about the TTIP, its provisions relating to life sciences, and the role of the pharmaceutical industry. This document aims to address some of the myths, and to highlight the benefits of increased transatlantic cooperation through the TTIP.